{
  "ticker": "JNJ",
  "target_date": "2025-10-28",
  "actual_date": "2025-10-28",
  "collected_at": "2025-12-08T12:27:35.898462",
  "price": {
    "open": 188.07,
    "high": 188.31,
    "low": 185.44,
    "close": 185.75062561035156,
    "volume": 8329500,
    "change_1d_pct": -1.77,
    "change_7d_pct": -3.26,
    "change_30d_pct": 5.93
  },
  "technicals": {
    "rsi_14": 39.97,
    "sma_20": 189.1,
    "sma_50": 181.5,
    "macd": 2.464,
    "macd_signal": 3.304,
    "macd_histogram": -0.84,
    "bb_upper": 193.61,
    "bb_lower": 184.6,
    "price_vs_sma20_pct": -1.77,
    "price_vs_sma50_pct": 2.34,
    "volume_ratio": 0.99
  },
  "fundamentals": {
    "market_cap": 487569031168,
    "pe_ratio": 19.533785,
    "forward_pe": 19.091509,
    "price_to_book": 6.142289,
    "price_to_sales": 5.2910943,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.62,
    "pct_from_52w_low": 43.85
  },
  "macro": {
    "spy": {
      "price": 687.06,
      "change_1d_pct": 0.27,
      "change_7d_pct": 2.35
    },
    "vix": {
      "level": 16.42,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 3.98
    },
    "dollar_index": {
      "level": 98.69
    },
    "gold": {
      "price": 3966.2
    },
    "regime": "BULL_LOW_VOL"
  },
  "news": [
    {
      "headline": "Levin Papantonio Announces Jury Awards $20 Million Verdict in Talc Mesothelioma Case Casaretto Estate v. Johnson & Johnson",
      "source": "Yahoo",
      "datetime": 1761689700,
      "summary": "Levin Papantonio legal team Levin Papantonio attorneys Cameron Stephenson, Chris Tisi, and Sara Papantonio FORT LAUDERDALE, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) -- A jury today awarded $20 million to the family of Dr. Alberto A. Casaretto, finding that Johnson & Johnson\u2019s talc-based products caused ",
      "url": "https://finnhub.io/api/news?id=0aca483863fbe14d065d44f8b1df4ff2a016a9148336bdf77216bde4a0a9a8ea"
    },
    {
      "headline": "Is Johnson & Johnson\u2019s Share Price Justified After Recent Surge in 2025?",
      "source": "Yahoo",
      "datetime": 1761682461,
      "summary": "Trying to figure out whether to buy, sell, or hold Johnson & Johnson? You are not alone. The stock price has been on a bit of a rollercoaster lately, closing most recently at $190.3. After a dip of 1.8% this past week, J&J is still up an impressive 5.9% over the last month, 32.1% year to date, and 2",
      "url": "https://finnhub.io/api/news?id=b140facf4615a614c6a1abd449f2ca631d0f3a9aa53fae485ebe2305e27f5172"
    },
    {
      "headline": "Texas Suit Accuses Tylenol Maker of Hiding a Link to Autism",
      "source": "Yahoo",
      "datetime": 1761677040,
      "summary": "The suit alleges that Kenvue hid autism risks of its popular pain reliever despite doctors saying it is safe to take during pregnancy.",
      "url": "https://finnhub.io/api/news?id=19488faf984089270cc088d24bcffc55f9f8c84cb31974e4bb6aa4d9b80a767a"
    },
    {
      "headline": "Tylenol Is Tied to Autism, Texas Claims in Suit. Kenvue Stock Shudders.",
      "source": "Yahoo",
      "datetime": 1761668760,
      "summary": "Texas joined the Trump administration in claiming Tylenol causes autism.  Shares of  Kenvue  fell 3.2% Tuesday to $14.60 after Texas Attorney General Ken Paxton filed a suit alleging that the maker of Tylenol engaged in deceptive advertising that said the over-the-counter drug was safe to use while ",
      "url": "https://finnhub.io/api/news?id=a9afdf34658779b22b98b57ba923753f409c7d8ab0cf3ea090853893dcf87805"
    },
    {
      "headline": "H.C. Wainwright Maintains a Buy on Halozyme Therapeutics (HALO), Keeps the PT at $90",
      "source": "Yahoo",
      "datetime": 1761668648,
      "summary": "Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) on October 21, keeping the associated price target the same at $90. The analyst supported the op",
      "url": "https://finnhub.io/api/news?id=16158a5dd6d886b34d572b63bbf11fce915acf6231e483929566c3de5e5d2d9b"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "10-Q",
      "date": "2025-10-22",
      "description": "jnj-20250928.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000209/jnj-20250928.htm"
    },
    {
      "form": "4",
      "date": "2025-10-20",
      "description": "xslF345X05/wk-form4_1761002033.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000204/xslF345X05/wk-form4_1761002033.xml"
    },
    {
      "form": "8-K",
      "date": "2025-10-14",
      "description": "jnj-20251014.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000201/jnj-20251014.htm"
    },
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627547.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000196/xslF345X05/wk-form4_1757627547.xml"
    },
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627315.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000194/xslF345X05/wk-form4_1757627315.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}